Exact Sciences Corp. (NASDAQ:EXAS) was up 6.1% on Tuesday . The stock traded as high as $13.49 and last traded at $13.37, with a volume of 5,360,848 shares traded. The stock had previously closed at $12.60.

Several research analysts have recently issued reports on the company. Zacks Investment Research raised Exact Sciences Corp. from a “hold” rating to a “buy” rating and set a $8.25 target price for the company in a research report on Tuesday, April 26th. Canaccord Genuity reissued a “buy” rating and issued a $9.00 target price on shares of Exact Sciences Corp. in a research report on Monday, May 2nd. Mizuho lowered Exact Sciences Corp. from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $12.00 to $6.50 in a research report on Wednesday, May 4th. Jefferies Group reissued a “buy” rating on shares of Exact Sciences Corp. in a research report on Wednesday, May 4th. Finally, BTIG Research reissued a “buy” rating on shares of Exact Sciences Corp. in a research report on Tuesday, May 10th. Eight research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $10.17.

The company has a 50 day moving average price of $9.49 and a 200-day moving average price of $7.33. The firm’s market capitalization is $1.32 billion.

Exact Sciences Corp. (NASDAQ:EXAS) last posted its earnings results on Tuesday, May 3rd. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.03. The firm had revenue of $14.80 million for the quarter, compared to analysts’ expectations of $15.17 million. The company’s revenue was up 244.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.40) earnings per share. On average, equities research analysts expect that Exact Sciences Corp. will post ($2.00) earnings per share for the current year.

Other large investors have recently bought and sold shares of the company. California State Teachers Retirement System raised its stake in Exact Sciences Corp. by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 177,702 shares of the company’s stock valued at $1,640,000 after buying an additional 2,809 shares during the last quarter. US Bancorp DE raised its position in shares of Exact Sciences Corp. by 2.3% in the fourth quarter. US Bancorp DE now owns 229,594 shares of the company’s stock worth $2,119,000 after buying an additional 5,109 shares in the last quarter. OppenheimerFunds Inc. raised its position in shares of Exact Sciences Corp. by 455.5% in the fourth quarter. OppenheimerFunds Inc. now owns 2,777,430 shares of the company’s stock worth $25,636,000 after buying an additional 2,277,430 shares in the last quarter. Finally, Eagle Asset Management bought a new position in shares of Exact Sciences Corp. during the third quarter worth $39,880,000.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.